natgillin/translations-raw huggingface dataset:
Individual components of the primary composite endpoint CV death** 
Posamezni dogodki primarnega sestavljenega cilja opazovanja kardiovaskularna smrt** prva hospitalizacija zaradi srčnega popuščanja
Angioedema has been reported in patients treated with Neparvis. 
Pri bolnikih, ki so prejemali zdravilo Neparvis, so poročali o angioedemu.
Neparvis 49 mg/51 mg film-coated tablets sacubitril/valsartan 
Neparvis 49 mg/51 mg filmsko obložene tablete sakubitril/valsartan
Neparvis 97 mg/103 mg film-coated tablets sacubitril/valsartan 
Neparvis 97 mg/103 mg filmsko obložene tablete sakubitril/valsartan
Monitoring of serum potassium is recommended if Neparvis is co-administered with these agents (see section 4.4). 
Pri sočasni uporabi zdravila Neparvis in navedenih zdravil je priporočeno spremljanje vrednosti kalija v serumu (glejte poglavje 4.4).
How to store Neparvis 
Shranjevanje zdravila Neparvis
• spinning sensation 
• izguba zavesti
Neparvis may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins. 
Substrati prenašalcev OATP1B1 in OATP1B3, na primer statini Podatki in vitro kažejo, da sakubitril zavira prenašalca OATP1B1 in OATP1B3, zato bi zdravilo Neparvis lahko povečalo sistemsko izpostavljenost substratom OATP1B1 in OATP1B3, kot so statini.
Neparvis must not be started until 36 hours after taking the last dose of ACE inhibitor therapy. 
Zdravljenja z zdravilom Neparvis se ne sme začeti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
A slight generalised delay in ossification was observed at doses of >50 mg/kg/day. 
Pri odmerkih >50 mg/kg/dan so opažali blago generalizirano zakasnitev zakostenevanja.
Each film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex). 
Ena filmsko obložena tableta vsebuje 48,6 mg sakubitrila in 51,4 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Neparvis must not be administered until 36 hours after discontinuing ACE inhibitor therapy. 
Zdravila Neparvis se ne sme odmerjati prej kot po preteku 36 ur od prekinitve zdravljenja z zaviralcem ACE.
• high level of potassium in the blood (shown in a blood test) 
• visoka raven kalija v krvi (kar pokaže izvid krvne preiskave)
o Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex). 
o Ena 49 mg/51 mg filmsko obložena tableta vsebuje 48,6 mg sakubitrila in 51,4 mg valsartana v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Neparvis must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy. 
Zdravljenja z zdravilom Neparvis se ne sme uvesti prej kot po preteku 36 ur od odmerjanja zadnjega odmerka zaviralca ACE.
You must tell your doctor if you think that you are (or might become) pregnant. 
Zdravniku morate povedati, če mislite, da ste noseči ali da bi lahko zanosili.
Metabolism and nutrition disorders 
Presnovne in prehranske motnje hiperkaliemija*
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists. 
Zdravila Neparvis se ne sme odmerjati sočasno z zaviralcem ACE ali zaviralcem receptorjev angiotenzina II.
Neparvis 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000 
Neparvis 97 mg/103 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
Neparvis 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000 
Neparvis 49 mg/51 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) rumeni železov oksid (E172)
Each film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex). 
Ena filmsko obložena tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Neparvis 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000 
Neparvis 24 mg/26 mg filmsko obložene tablete hipromeloza, substitucijski tip 2910 (3 mPa·s) titanov dioksid (E171) makrogol 4000 smukec rdeči železov oksid (E172) črni železov oksid (E172)
Each 24 mg/26 mg tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex). 
Ena 24 mg/26 mg tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Therefore, co-administration of Neparvis with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, 
Iz tega razloga lahko sočasna uporaba zdravila Neparvis z zaviralci OATP1B1, OATP1B3, OAT3 (kot sta rifampicin in ciklosporin), OAT1 (kot sta tenofovir in cidofovir) ali MRP2 (kot je ritonavir) poveča sistemsko izpostavljenost substanci LBQ657 oziroma valsartanu.
Each 97 mg/103 mg tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex). 
Ena 97 mg/103 mg tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
• low level of potassium in the blood (shown in a blood test) 
• nizka raven kalija v krvi (kar pokaže izvid krvne preiskave)
Losartan 150 
Roonstrasse 25
o Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex). 
o Ena 24 mg/26 mg filmsko obložena tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex). 
Ena filmsko obložena tableta vsebuje 24,3 mg sakubitrila in 25,7 mg valsartana (v obliki kompleksa natrijeve soli sakubitrila in valsartana).
Neparvis 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side. 
Tablete so velike približno 13,1 mm x 5,2 mm. Neparvis 49 mg/51 mg filmsko obložene tablete so bledo rumene ovalne tablete z vtisnjenima oznakama "NVR" na eni strani in "L1" na drugi.
o Each 97 mg/103 mg film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex). 
o Ena 97 mg/103 mg filmsko obložena tableta vsebuje 97,2 mg sakubitrila in 102,8 mg valsartana v obliki kompleksa natrijeve soli sakubitrila in valsartana).
A starting dose of 24 mg/26 mg twice daily should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m2). 
1,4-krat oziroma 2,2-krat večja kot pri bolnikih z blago okvaro ledvic (60 ml/min/1,73 m
Gastrointestinal disorders 
Študija TITRATION
A similar effect on the heart rate may occur when Neparvis is co-administered with sublingual, oral or transdermal nitrates. 
Pri sočasni uporabi zdravila Neparvis in sublingvalne, peroralne ali transdermalne oblike nitratov lahko pride do podobnih učinkov na srčno frekvenco.
Renal impairment* 
Bolezni sečil okvara ledvic*
Your doctor may check the amount of potassium in your blood at regular intervals during Neparvis treatment. 
V času zdravljenja z zdravilom Neparvis vam bo zdravnik verjetno redno preverjal koncentracijo kalija v krvi.
• dizziness 
• vrtoglavica
Do not take Neparvis with ACE inhibitors. 
• zaviralcev ACE: zdravila Neparvis ne smete jemati sočasno z zaviralci ACE.
All-cause mortality 711 (16.98) 835 (19.82) 0.84 (0.76, 0.93) 16% 0.0005 *The primary endpoint was defined as the time to first event of CV death or hospitalisation for HF. **CV death includes all patients who died up to the cut-off date irrespective of previous hospitalisation. 
Sekundarni cilj opazovanja umrljivost iz kateregakoli vzroka * primarni cilj opazovanja je bil opredeljen kot čas do prvega od dveh dogodkov: kardiovaskularne smrti ali hospitalizacije zaradi srčnega popuščanja ** kardiovaskularna smrt vključuje vse bolnike, ki so umrli do vnaprej določenega datuma ne glede na predhodne hospitalizacije *** vrednost p za enostranski test skupina bolnikov za celotno analizo (angl. full analysis set)
Fatigue 
• utrujenost
Impaired hepatic function 
Žilne bolezni hipotenzija*
This overview was last updated in 03-2019. 
Povzetek je bil nazadnje posodobljen 03-2019.
Further information on Revolade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Revolade. 
Nadaljnje informacije o zdravilu Revolade so na voljo na spletni strani agencije:ema.europa.eu/medicines/human/EPAR/Revolade.
Revolade received a marketing authorisation valid throughout the EU on 11 March 2010. 
Za zdravilo Revolade je bilo 11. marca 2010 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
What measures are being taken to ensure the safe and effective use of Revolade? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Revolade?
Revolade is a medicine that is used for the treatment of: 
Revolade je zdravilo, ki se uporablja za zdravljenje:
The European Medicines Agency decided that Revolade's benefits are greater than its risks and recommended that it be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Revolade večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Revolade 
Druge informacije o zdravilu Revolade
As for all medicines, data on the use of Revolade are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Revolade stalno spremljajo.
What benefits of Revolade have been shown in studies? 
Kakšne koristi je zdravilo Revolade izkazalo v študijah?
An extension of the study found that Revolade was effective at maintaining adequate levels of platelets in the long term. 
V podaljšanju študije so ugotovili, da je bilo zdravilo Revolade učinkovito tudi za dolgoročno ohranjanje ustreznih ravni trombocitov.
Severe aplastic anaemia 
Huda aplastična anemija
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Revolade have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Revolade upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
An overview of Revolade and why it is authorised in the EU 
Pregled zdravila Revolade in zakaj je odobreno v EU
Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks. 
Predhodni rezultati podporne študije se ujemajo z rezultati glavne študije, saj se je po 12 tednih na zdravljenje odzvalo 46 % bolnikov.
For the treatment of thrombocytopenia associated with hepatitis C, two main studies involving a total of 1,441 adults were carried out. 
V zvezi z zdravljenjem trombocitopenije, povezane s hepatitisom C, sta bili izvedeni dve glavni študiji, v katerih je sodelovalo skupno 1 441 odraslih.
The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating blood diseases or chronic hepatitis C and its complications. 
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem krvnih obolenj ali kroničnega hepatitisa C in z njim povezanih zapletov.
Why is Revolade authorised in the EU? 
Zakaj je zdravilo Revolade odobreno v EU?
What are the risks associated with Revolade? 
Kakšna tveganja so povezana z zdravilom Revolade?
Revolade is available as tablets (12.5, 25, 50 and 75 mg) and as a powder (25 mg) to prepare a suspension (a liquid) to be taken by mouth. 
Zdravilo Revolade je na voljo v obliki tablet (12,5 mg, 25 mg, 50 mg in 75 mg) in praška (25 mg) za pripravo suspenzije (tekočine) za peroralno uporabo.
For the treatment of severe aplastic anaemia, Revolade was studied in 43 patients and it was not compared with any other medicine. 
V zvezi z zdravljenjem hude aplastične anemije so uporabo zdravila Revolade proučevali pri 43 bolnikih in ga niso primerjali z nobenim drugim zdravilom.
What is Revolade and what is it used for? 
Kaj je zdravilo Revolade in za kaj se uporablja?
For more information about using Revolade, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Revolade glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Revolade are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Revolade, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Revolade is used in patients from 1 year of age who have had the disease for at least 6 months and for whom treatment with medicines such as corticosteroids or immunoglobulins has not worked; 
Zdravilo Revolade se uporablja pri bolnikih od enega leta dalje, ki so bolni najmanj šest mesecev in pri katerih zdravljenje z zdravili, kot so kortikosteroidi ali imunoglobulini, ni delovalo;
For ITP and aplastic anaemia, a lower starting dose should be used in patients of Asian descent (such as Chinese, Japanese, Korean or Taiwanese people). 
Pri imunski trombocitopenični purpuri in aplastični anemiji je treba pri bolnikih azijskega porekla (kot so Kitajci, Japonci, Korejci ali Tajvanci) uporabiti manjši začetni odmerek.
In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment. 
Glavno merilo učinkovitosti v obeh študijah je bilo število bolnikov, pri katerih krvne preiskave šest mesecev po zaključku zdravljenja niso pokazale nobenih znakov prisotnosti virusa hepatitisa C.
Thrombocytopenia associated with hepatitis C 
Trombocitopenija, povezana s hepatitisom C
Revolade is used in adult patients whose disease is not controlled by immunosuppressive therapy (medicines that lower the body's immune defences) and cannot receive haematopoietic stem cell transplantation (where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow). 
Zdravilo Revolade se uporablja pri odraslih, katerih bolezen ni nadzorovana z imunosupresivno terapijo (zdravili, ki znižujejo imunsko obrambo telesa) in pri katerih ni mogoče opraviti presaditve hematopoetskih matičnih celic (kadar se bolnikov kostni mozeg nadomesti z izvornimi celicami darovalca, ki tvorijo nov kostni mozeg).
In these two studies, a higher proportion of patients who took Revolade tested negative for hepatitis C, compared with those who took placebo (23% versus 14% in the first study, and 19% versus 13% in the second study). 
V teh dveh študijah je bil test prisotnosti virusa hepatitisa C negativen pri večjem deležu bolnikov, ki so jemali zdravilo Revolade, kot pri bolnikih, ki so prejemali placebo (23 % v primerjavi s 14 % v prvi študiji in 19 % v primerjavi s 13 % v drugi študiji).
• acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells or platelets). 
• pridobljene hude aplastične anemije (bolezni, pri kateri kostni mozeg ne tvori dovolj krvnih celic ali trombocitov).
The most important serious side effects are febrile neutropenia (low white blood cell counts with fever) and infection. 
Najpomembnejši resni neželeni učinki so febrilna nevtropenija (nizko število belih krvnih celic s povišano telesno temperaturo) in okužba.
Revolade contains the active substance eltrombopag. 
Zdravilo Revolade vsebuje učinkovino eltrombopag.
For the treatment of ITP in adults, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 patients who had previously been treated, but the treatments had not worked or the disease had come back. 
Za zdravljenje imunske trombocitopenične purpure pri odraslih so zdravilo Revolade primerjali s placebom (zdravilom brez učinkovine) v dveh glavnih študijah, ki sta vključevali skupno 311 predhodno zdravljenih bolnikov, pri katerih zdravljenje ni delovalo ali pa se je bolezen ponovila.
For the full list of restrictions and side effects of Revolade, see the package leaflet. 
Za celoten seznam omejitev in neželenih učinkov zdravila Revolade glejte navodilo za uporabo.
Important serious side effects are liver problems and thromboembolic complications. 
Pomembni resni neželeni učinki so težave z jetri in trombembolični zapleti.
Revolade was more effective than placebo: in the first study, 59% of the patients who took Revolade (43 out of 73) achieved a platelet count of at least 50,000 per microlitre (which is considered adequate to prevent bleeding complications) after 6 weeks of treatment, compared with 16% of those who took placebo (6 out of 37). 
Zdravilo Revolade je bilo učinkovitejše od placeba: v prvi študiji je število trombocitov pri 59 % (43 od 73) bolnikov, ki so jemali zdravilo Revolade, po šestih tednih zdravljenja doseglo vsaj 50 000 trombocitov na mikroliter (kar šteje kot zadostno za preprečevanje zapletov s krvavitvami), pri bolnikih, ki so jemali placebo, pa je bilo takšnih 16 % (6 od 37).
• primary immune thrombocytopenia (ITP), a disease in which the patient's immune system destroys platelets (components in the blood that help it to clot). 
• primarne imunske trombocitopenične purpure, tj. bolezni, pri kateri bolnikov imunski sistem uničuje trombocite (sestavino krvi, ki sodeluje pri njenem strjevanju).
These compared Revolade with placebo for allowing the starting and maintenance of antiviral treatment in patients with hepatitis C whose platelet count was initially too low to allow starting such treatment (less than 75,000 per microlitre). 
V okviru teh študij so zdravilo Revolade primerjali s placebom, da bi ugotovili, ali omogoča začetno in vzdrževalno protivirusno zdravljenje pri bolnikih s hepatitisom C, katerih število trombocitov je bilo ob začetku zdravljenja prenizko, da bi lahko pri njih uvedli tovrstno terapijo (nižje od 75 000 na mikroliter).
The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se po 12 ali 16 tednih zdravljenja odzvali na zdravilo Revolade (pri katerih je število trombocitov ter rdečih in belih krvnih celic ostalo nad predhodno določenimi ravnmi).
The most important serious side effects are liver problems and thromboembolic complications (problems with clots in blood vessels). 
Najpomembnejši resni neželeni učinki so težave z jetri in trombembolični zapleti (težave s strdki v krvnih žilah).
The most common side effects with Revolade in adults with ITP (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea and abnormal blood levels of certain liver enzymes. 
Najpogostejši neželeni učinki zdravila Revolade pri odraslih z imunsko trombocitopenično purpuro (ki lahko prizadenejo več kot 1 osebo od 10) so navzeja (slabost), driska in nenormalne ravni nekaterih jetrnih encimov v krvi.
How is Revolade used? 
Kako se zdravilo Revolade uporablja?
How does Revolade work? 
Kako zdravilo Revolade deluje?
The active substance in Revolade, eltrombopag, also attaches to and stimulates the thrombopoietin receptors. 
Učinkovina v zdravilu Revolade, eltrombopag, se tudi veže na receptorje trombopoetina in v njih povzroči enak spodbujevalni učinek.
This study lasted 13 weeks and looked at the proportion of patients whose platelet count had increased to at least 50,000 per microlitre for at least 6 out of 8 weeks, between week 5 to 12 of the study in the absence of rescue medication. 
V študiji, ki je trajala 13 tednov, so proučevali delež bolnikov, pri katerih se je število trombocitov povečalo za vsaj 50 000 na mikroliter v najmanj šestih tednih od osmih med petim in dvanajstim tednom študije brez olajševalnega zdravila.
In the body, a hormone called ‘thrombopoietin' stimulates the production of platelets by attaching to certain receptors (targets) in the bone marrow. 
V telesu nastajanje trombocitov spodbuja hormon trombopoetin, tako da se veže na določene receptorje (prijemališča) v kostnem mozgu.
This occurred in around 40% of those taking Revolade (25 out of 63) compared with around 3% (1 out of 29) of those who took placebo. 
Do tega je prišlo pri približno 40 % (25 od 63) bolnikov, ki so jemali zdravilo Revolade, pri tistih, ki so jemali placebo, pa pri približno 3 % (pri 1 od 29).
In patients with thrombocytopenia and advanced chronic hepatitis C who are treated with interferon and Revolade, the most common side effects include headache, anaemia (low red blood cell counts), decreased appetite, cough, nausea, diarrhoea, high levels of bilirubin in the blood, hair loss, itching, muscle pain, fever, tiredness, flu-like illness, weakness, chills and swelling (because of build-up of water in the body). 
Pri bolnikih s trombocitopenijo in napredovalim kroničnim hepatitisom C, ki se zdravijo z interferonom in zdravilom Revolade, so najpogostejši neželeni učinki glavobol, anemija (nizko število rdečih krvnih celic), zmanjšan tek, kašelj, siljenje na bruhanje, driska, visoke ravni bilirubina v krvi, izpadanje las, srbenje, bolečine v mišicah, povišana telesna temperatura, utrujenost, gripi podobna bolezen, šibkost, mrzlica in otekanje (zaradi kopičenja vode v telesu).
In children with ITP, Revolade was more effective than placebo in one main study involving 92 children between 1 and 17 years of age who had previously been treated for ITP. 
Pri otrocih z imunsko trombocitopenično purpuro je bilo v eni glavni študiji, ki je vključevala 92 predhodno zdravljenih otrok, starih od enega do 17 let, zdravilo Revolade učinkovitejše od placeba.
The dose depends on the patient's age and the disease for which Revolade is being used; it is adjusted as needed to maintain the appropriate platelet level. 
Odmerek je odvisen od starosti bolnika in bolezni, za katero se zdravilo Revolade uporablja.
In this study, 40% of patients (17 out of 43) responded to treatment after 12 weeks, and in 65% of them (11 out of 17) the platelet count either increased by at least 20,000 per microliter or it was stable without a need for blood transfusions. 
Pri 65 % (11 od 17) vseh, ki so se odzvali, se je število trombocitov bodisi povečalo za vsaj 20 000 na mikroliter bodisi je bilo stabilno, ne da bi bila potrebna transfuzija krvi.
In adults with severe aplastic anaemia the most common side effects include headache, dizziness, cough, pain in the belly or in the mouth and throat, nausea, diarrhoea, joint pain, pain in limbs, tiredness, fever and abnormal blood levels of certain liver enzymes. 
Pri odraslih z resno aplastično anemijo so najpogostejši neželeni učinki glavobol, omotica, kašelj, bolečina v trebuhu ali v ustih in žrelu, siljenje na bruhanje, driska, bolečine v sklepih, bolečine v udih, utrujenost, povišana telesna temperatura in nenormalne ravni nekaterih jetrnih encimov v krvi.
Patients should not take medicines such as antacids or dairy products and mineral supplements in the 4 hours before and in the 2 hours after taking Revolade. 
Štiri ure pred jemanjem zdravila Revolade in dve uri po njem bolniki ne smejo zaužiti antacidov, mlečnih izdelkov ali mineralnih prehranskih dopolnil.
Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding. 
Bolniki z imunsko trombocitopenično purpuro imajo nizko število trombocitov v krvi (trombocitopenijo) in povečano tveganje za krvavitve.